AGMB-129 + Placebo
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fibrostenotic Crohn's Disease
Conditions
Fibrostenotic Crohn's Disease
Trial Timeline
Aug 1, 2023 → Sep 1, 2026
NCT ID
NCT05843578About AGMB-129 + Placebo
AGMB-129 + Placebo is a phase 2 stage product being developed by Agomab Therapeutics for Fibrostenotic Crohn's Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05843578. Target conditions include Fibrostenotic Crohn's Disease.
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05843578 | Phase 2 | Active |
Competing Products
1 competing product in Fibrostenotic Crohn's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AGMB-129 | Agomab Therapeutics | Phase 1 | 23 |